CO2023007335A2 - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents
Ácidos pirazol piperidin carboxílicos sustituidosInfo
- Publication number
- CO2023007335A2 CO2023007335A2 CONC2023/0007335A CO2023007335A CO2023007335A2 CO 2023007335 A2 CO2023007335 A2 CO 2023007335A2 CO 2023007335 A CO2023007335 A CO 2023007335A CO 2023007335 A2 CO2023007335 A2 CO 2023007335A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- hfref
- carboxylic acids
- heart
- disease
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 3
- 208000008960 Diabetic foot Diseases 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- KPVQNXLUPNWQHM-RBEMOOQDSA-N 3-acetylpyridine adenine dinucleotide Chemical compound CC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 KPVQNXLUPNWQHM-RBEMOOQDSA-N 0.000 abstract 1
- CANSPPZTVXEOJH-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxylic acid Chemical class C1CCNC2=C1NN=C2C(=O)O CANSPPZTVXEOJH-UHFFFAOYSA-N 0.000 abstract 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023007335A2 true CO2023007335A2 (es) | 2023-06-09 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0007335A CO2023007335A2 (es) | 2020-12-10 | 2023-06-02 | Ácidos pirazol piperidin carboxílicos sustituidos |
Country Status (30)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN119300815A (zh) | 2022-06-09 | 2025-01-10 | 拜耳公司 | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 |
| JP2026504406A (ja) * | 2023-01-31 | 2026-02-05 | インビボサイエンシーズ インコーポレイテッド | 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法 |
| AU2024348074A1 (en) * | 2023-09-27 | 2026-04-30 | Haisco Pharmaceutical Group Co., Ltd. | Pyrazole carboxylic acid derivative and use thereof in medicine |
| TW202535380A (zh) * | 2024-01-30 | 2025-09-16 | 大陸商海思科醫藥集團股份有限公司 | 吡唑羧酸衍生物及其在醫藥上的應用 |
| WO2026145681A1 (zh) * | 2025-01-03 | 2026-07-09 | 上海齐鲁制药研究中心有限公司 | 杂环羧酸类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| ES2635340T3 (es) | 2010-02-27 | 2017-10-03 | Bayer Intellectual Property Gmbh | Ariltriazolonas ligadas a bis-arilo y su uso |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| MX338887B (es) * | 2012-09-07 | 2016-05-04 | Boehringer Ingelheim Int | Alcoxipirazoles como activadores de guanilato ciclasa soluble. |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| US20170313665A1 (en) | 2014-11-03 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CA3204595A1 (en) * | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
| WO2022122917A1 (en) * | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2021
- 2021-12-09 CN CN202180081892.0A patent/CN116710439B/zh active Active
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000115A (es) | Ácidos pirazol piperidin carboxílicos sustituidos | |
| DOP2023000114A (es) | Ácidos pirazolo piperidin carboxílicos sustituidos | |
| Jia et al. | Arterial stiffness: a nexus between cardiac and renal disease | |
| MX2010000927A (es) | Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos. | |
| Xiao et al. | Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects | |
| AR061996A1 (es) | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular | |
| EA201171361A1 (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
| NZ715983A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| UY31310A1 (es) | Ácidos 6-fenilnicotínicos sustituidos y su uso | |
| BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
| EP4488371A3 (en) | Compounds and methods for modulating angiotensinogen expression | |
| Milio et al. | Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs | |
| WO2008096816A1 (ja) | 血管新生誘導剤及びそれに用いられるポリペプチド | |
| PE20191465A1 (es) | Composicion farmaceutica que comprende acido 2,5-dihidroxibencenosulfonico o una de sus sales farmaceuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricacion correspondiente | |
| WO2011132161A3 (en) | Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved | |
| BR112014005518A2 (pt) | 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos | |
| BR0315458A (pt) | Utilização de tenatoprazol | |
| Ali | Hypertensive vascular disease | |
| CL2022002838A1 (es) | Derivado de arilo o heteroarilo | |
| Banerjee et al. | Comparison of Echocardiographic Patterns between Mild to Moderate and Severe CKD with type 4 Cardio renal Syndrome Patients | |
| Otaki et al. | Plasma thioredoxin-1 level is associated with renal tubular damage and predicts poor prognosis in patients with chronic heart failure | |
| MARKER | THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY CHENNAI-600 032 | |
| TH102589B (th) | อนุพันธ์กรดไซโคลเพนเทนคาร์บอกซิลิกที่เชื่อมต่อกันซึ่งถูกแทนที่ด้วยเอซิลอะมิโน และการใช้สารดังกล่าวเป็นสารทางเภสัชกรรม | |
| WO2018051294A3 (en) | Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies | |
| TH137791A (th) | อนุพันธ์กรดไซโคลเพนเทนคาร์บอกซิลิกที่เชื่อมต่อกันซึ่งถูกแทนที่ด้วยเอซิลอะมิโน และการใช้สารดังกล่าวเป็นสารทางเภสัชกรรม |